{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:37:41Z","timestamp":1725669461497},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/cco.0b013e328358f602","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T07:36:22Z","timestamp":1347003382000},"page":"742-747","source":"Crossref","is-referenced-by-count":9,"title":["Advances in the management of follicular lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Till M.","family":"Seiler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210128","first-page":"3909","article-title":"The Non-Hodgkins Lymphoma Classification Project.","volume":"89","year":"1997","journal-title":"Blood"},{"key":"R2-21-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","article-title":"The microenvironment in follicular lymphoma.","volume":"24","author":"de Jong","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-21-20210128","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R4-21-20210128","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-21-20210128","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R7-21-20210128","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"R8-21-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R9-21-20210128","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkins lymphomas.","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe dEtude des Lymphomes Folliculaires. Groupe dEtude des Lymphomes de lAdulte.","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"R14-21-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis.","volume":"116","author":"Ardeshna","year":"2010","journal-title":"Blood"},{"key":"R15-21-20210128","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national Lympho Care study.","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-21-20210128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the groupe detude des lymphomes de ladulte.","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"key":"R18-21-20210128","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMOIIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"R19-21-20210128","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2011","journal-title":"Blood"},{"key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkins lymphoma: results from a phase II multicenter, single-agent study.","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-21-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.","volume":"116","author":"Kahl","year":"2011","journal-title":"Cancer"},{"key":"R22-21-20210128","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkins lymphoma.","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-21-20210128","doi-asserted-by":"crossref","first-page":"abstract405","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and complete remission rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced Follicular, indolent, and Mantle Cell Lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"R24-21-20210128","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkins lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.","volume":"18","author":"Fisher","year":"2000","journal-title":"J Clin Oncol"},{"key":"R25-21-20210128","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","article-title":"Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkins lymphoma: results from a prospective, multicenter trial with double randomization.","volume":"16","author":"Arranz","year":"1998","journal-title":"J Clin Oncol"},{"key":"R26-21-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkins lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"J Clin Oncol"},{"key":"R27-21-20210128","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"R28-21-20210128","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkins lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network.","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-21-20210128","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsedresistant follicular non-Hodgkins lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"R30-21-20210128","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R31-21-20210128","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","article-title":"Results of eastern cooperative oncology group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma.","volume":"118","author":"Kahl","year":"2011","journal-title":"Blood"},{"key":"R32-21-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428194.2011.608446","article-title":"Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.","volume":"53","author":"Herold","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R33-21-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera).","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R34-21-20210128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"R35-21-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood.V118.21.269.269","article-title":"Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell Non-Hodgkin Lymphoma: preliminary analysis of the GAUSS study.","volume":"118","author":"Sehn","year":"2011","journal-title":"Blood"},{"key":"R36-21-20210128","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"R37-21-20210128","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"R38-21-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.","volume":"152","author":"Patz","year":"2011","journal-title":"Br J Haematol"},{"key":"R39-21-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101.","volume":"10","author":"Dalle","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R40-21-20210128","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"key":"R41-21-20210128","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1182\/blood.V116.21.2868.2868","article-title":"Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsedrefractory indolent NHL (iNHL).","volume":"116","author":"Salles","year":"2010","journal-title":"Blood"},{"key":"R42-21-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-9822(06)00057-1","article-title":"CD22 is a negative regulator of B-cell receptor signalling.","volume":"7","author":"Nitschke","year":"1997","journal-title":"Curr Biol"},{"key":"R43-21-20210128","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase III trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkins lymphoma.","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"R44-21-20210128","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkins lymphoma.","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"R45-21-20210128","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"key":"R46-21-20210128","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","article-title":"Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20CD22 antibodies in lymphoma.","volume":"113","author":"Rossi","year":"2009","journal-title":"Blood"},{"key":"R47-21-20210128","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2007-08-110072","article-title":"Bispecific anti-CD2022 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.","volume":"111","author":"Qu","year":"2008","journal-title":"Blood"},{"key":"R48-21-20210128","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase III study in non-Hodgkins lymphoma.","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J Clin Oncol"},{"key":"R49-21-20210128","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkins lymphoma: results of a phase I study.","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"R50-21-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"R51-21-20210128","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"15s","key":"R52-21-20210128","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/jco.2010.28.15_suppl.8012","article-title":"Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"s2","key":"R53-21-20210128","first-page":"466","article-title":"Clinical activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phophatidylinositol 2-Kinase p110delta, in patients with B-cell malignancies.","volume":"95","author":"Brown","year":"2010","journal-title":"Haematologica"},{"key":"R54-21-20210128","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells.","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R55-21-20210128","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkins Lymphoma.","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"R56-21-20210128","doi-asserted-by":"crossref","first-page":"abstract1679","DOI":"10.1182\/blood.V114.22.1679.1679","article-title":"R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsedrefractory indolent Non-Hodgkins Lymphoma (NHL).","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood"},{"key":"R57-21-20210128","doi-asserted-by":"crossref","first-page":"abstract8036","DOI":"10.1200\/jco.2010.28.15_suppl.8036","article-title":"Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkins lymphoma.","volume":"28","author":"Fowler","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e328358f602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:37:47Z","timestamp":1714351067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201211000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328358f602","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}